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Evidence that resistance to the calcemic action of
parathyroid hormone in rats with acute uremia is caused by
phosphate retention
PETERJ. SOMERVILLE and MICHAEL KAYE
Department of Medicine, Division of Nephrology, Montreal General Hospital, Montreal, Quebec, Canada
Evidence that resistance to the calcemic action of parathyroid
hormone in rats with acute uremia is caused by phosphate reten-
tion. An animal model was developed to examine the cause of
resistance to the calcemic action of PTH in renal failure. Thyro-
parathyroidectomized (TPTX) rats were repeatedly reinfused
with their excreted urine, over a 5-hour period, to produce an
acute uremic animal with normal kidneys. Nonuremic controls
were infused with equivalent volumes of a simple electrolyte so-
lution. Using this model, we have demonstrated impaired cal-
cemic response to PTH (Lilly Parathyroid Extract, 80 UIl00 g) in
urine-infused rats compared with electrolyte-infused rats. The fi-
nal plasma calcium concentrations were 12.0 0.3 and 14.9
0.3 mg/dl, respectively (P < 0.001). The cause of this impaired
calcemic response was investigated by reinfusing rats with their
own urine that had been pretreated with either activated charcoal
or zirconium oxide in two different anionic forms, or urine that
had been ultrafiltrated through an Amicon membrane of which
the stated molecular-weight cut-off of the smallest pore-size
membrane was 500 daltons. It was found that charcoal and ultra-
filtration techniques had no effect, whereas the zirconium oxide
treatment completely corrected the impaired calcemic response
and returned the plasma phosphorus to a concentration similar to
that in nonuremic controls. This can be explained by the fact that
the principal effect of zirconium oxide on urine is to remove in-
organic phosphate. Other groups of TPTX rats given PTH ex-
tract were infused with an electrolyte solution containing varying
amounts of phosphate up to a maximum similar to the amount
that a urine-infused rat would receive. A highly significant in-
verse relationship was found between the dose of phosphate in-
fused with the electrolyte solution and the measured calcemic
response to PTH. This relationship is represented by the follow-
ing equation: calcium (mg/dl) = 14.84 — 0.139 inorganic phos-
phate; r 0.915, P < 0.001. From these series of studies, we
conclude that phosphate retention is the cause of resistance to
the calcemic action of PTH extract in this acute uremic model.
Preuve de ce que Ia résistance a I'action hypercalcémiante de
l'hormone parathyroIdienne, chez le rat en urémie aiguë, est dé-
terminée par Ia retention de phosphate. Un modéle animal a été
développé pour étudier Ia cause de Ia résistance a l'action hyper-
calcémiante de Ia PTH au cours de l'insuffisance rénale. Des rats
thyroparathyroIdectomisés (TPTX) ont été perfusés avec leur
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propre urine, de facon iterative, pendant une période de 5
heures, afin de produire une urémie aigue avec des reins nor-
maux. Les contrôles non uremiques ont été perfusés avec un
volume equivalent d'une solution electrolytique. Au moyen de
ce modèle nous avons démontré une alteration de Ia réponse du
calcium plasmatique a 80 U/100 g d'extrait PTH (Lilly) chez les
rats perfusés avec de l'urine par comparaison avec les contrôles.
Les calcémies finales étaient de 12,0 0,3 et 14,9 0,3 mgldl,
respectivement (P < 0,001). La cause de cette alteration de la
réponse a été étudiée par l'infusion a des rats de leur urine preal-
ablement traitée par du charbon actif ou de I'oxyde de zirconium
sous deux formes anioniques différentes, ou par ultrafihitration a
travers une membrane Amicon dont he point le coupure théo-
rique est de 500 daltons. II a été constaté que Ic charbon active et
I'ultrafiltration n'ont pas d'effet alors que Ic traitement par
I'oxyde de zirconium corrige complètement la réponse du cal-
cium plasmatique et ramène le phosphore plasmatique a une va-
leur semblable a celle des contrôles non urémiques. Cela peut
étre exphique par he fait que l'effet principal de l'oxyde de zirco-
nium est de soustraite le phosphate mineral de l'urine. Dautres
groupes de rats TPTX recevant de l'extrait PTH ont etC perfusés
avec une solution d'électrolytes contenant des concentrations
différentes de phosphate, Ia plus élevCe étant semblable a celle
de l'urine qui aurait été utilisCe dans une infusion. Une relation
inverse trés significative a été constatée entre Ia quantité de
phosphate administrée et la réponse du calcium a Ia PTH. Cette
relation est représentée par l'équation suivante: calcium (mg/do
= 14,84 — 0,139 inorganic phosphate, r = 0,915, P < 0,001. De
ces résultats nous concluons que la retention de phosphate est la
cause de Ia résistance a l'action hypercalcémiante de l'extrait
PTH dans ce modele d'urémie aigue.
Resistance to the calcemic action of PTH in renal
failure is now a well-described entity both in man
[1-3] and in experimental animals [4, 5]. Although
the importance of this phenomenon as a factor in
the pathogenesis of the secondary hyperparathy-
roidism of renal failure is accepted [6], the mecha-
nism has not been explained completely. It has been
suggested that an abnormality in vitamin D metabo-
lism may have some role in this resistance, but, in
addition, a uremic factor or factors may also be in-
volved [7]. In a series of experiments recently re-
ported by this laboratory, we demonstrated PTH re-
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sistance in a 5-hour acute renal failure (ARF) rat
model and showed that such resistance was not
caused by an abnormality of vitamin D metabolism.
In the same report, we showed, however, that an
abnormality in vitamin D metabolism does play a
role in PTH resistance in rats with chronic renal
failure of 28 days' duration [8].
The current paper describes experiments de-
signed to determine the nature of the factors re-
sponsible for PTH resistance in rats with ARF. In
an unpublished study, we had previously demon-
strated that PTH resistance in renal failure caused
by 5 hours' bilateral ureter ligation was similar to
PTH resistance in rats with uremia induced by
simple ureter division and allowing the urine to
drain into the peritoneal cavity. This study sug-
gested that a factor present in the urine was respon-
sible for the resistance, rather than its being due to
abnormal metabolic function of the kidney. In addi-
tion, it seemed that the factor responsible would
probably be readily dialyzable, as it must have dif-
fused back through the peritoneal membranes of the
latter group to cause the resistance noted. The stud-
ies to be described were designed to determine the
nature of this factor in the urine, by using a uremic
rat model produced by urine reinfusion. With this
model we have been able to show that PTH resis-
tance is caused by retention of inorganic phos-
phorus.
Methods
Animal model. All studies were performed on
male Sprague-Dawley rats weighing between 150
and 180 g. The rats were fed a semisynthetic low-
calcium diet and were given water containing 5%
dextrose for 4 days prior to use. This diet has been
described previously [9] and has an analyzed cal-
cium content of 0.0 1%.
On all study days, each rat was given an oral fluid
load of 2 ml of 0.9% sodium chloride to ensure a
good urine flow. It was then anesthetized with pen-
tobarbital sodium, 0.09 mg/100 g body wt, the ure-
thra was ligated, and the bladder was cannulated
with flared PE-50 tubing, which was brought out
through the abdominal wall for urine collection.
Next, the animal was thyroparathyroidectomized
(TPTX), and PE-lO tubing was inserted into the left
jugular vein for infusion of urine or electrolyte solu-
tions.
During the 2 hours following the surgical proce-
dure, urine was collected from all animals, and they
were allowed to regain consciousness. At the end of
this period, the rats were injected with either Lilly
parathyroid extract (PTE) or an equivalent volume
of diluent, prepared as described previously [8]. Im-
mediately following the injection of hormone or
diluent, the urine collected during the previous 2
hours was reinfused over the next 30 mm, with a
variable speed constant infusion pump. The urine
collected during this 30 mm was then reinfused over
the next 30 mm. The 30-mm cycle was repeated
continuously for a total of 10 cycles; that is, until 5
hours had elapsed after injection of the hormone or
diluent. At the end of this 5-hour period, all rats
were lightly anesthetized with ether and killed by
bleeding from the abdominal aorta.
In the first 47 rats studied, the average total urine
volume excreted during the 5 hours following the
injection of hormone or diluent was found to be 15.7
1.4 ml. Occasionally, rats were noted to have ex-
creted a much smaller volume of urine during the 5-
hour period, usually between 2 and 4 ml, which was
frequently associated with a collection of fluid in the
pleural cavity. When either a pleural collection was
found, or if a rat had excreted a volume of urine less
than an arbitrarily fixed amount of 7 ml, the rat was
excluded from the study. Using this basic model,
three series of studies were carried out.
Series 1: Demonstration of parathyroid resis-
tance. In this series of studies a comparison was
made between the calcemic response to PTE in
urine-reinfused rats and nonuremic "control" rats.
Rats which served as nonuremic controls were not
reinfused with urine but instead were given an
equivalent volume of an electrolyte solution con-
taining: sodium, 75 mM/liter; potassium, 50 mM/li-
ter; and chloride, 125 mM/liter. Preliminary studies
had shown that this was the average electrolyte
concentration of the urine collected for reinfusion in
the former groups.
Series 2: Pretreatment of urine prior to reinfu-
sion. Three different techniques were used in an at-
tempt to remove the factor or factors responsible
for the parathyroid resistance. In the first, each
batch of urine was passed through an Amicon mem-
brane (Amicon Corporation, Lexington, Massachu-
setts) prior to reinfusion. Because of the dead space
in the Amicon cells, a priming volume of 1 ml of
urine was added to the cell at the commencement of
the filtration. This urine was obtained via a cys-
tostomy tube, from one or two "donor rats" taken
from the same experimental group. The "donor
rats" were neither TPTX nor given PTE. Amicon
membranes of theoretical mol-wt cut-offs of 20,000,
1,000, and 500 daltons were used.
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In the second technique, each batch of urine was
treated with activated charcoal prior to reinfusion.
The urine was mixed with Norit A charcoal, 150 mgI
ml of urine, in a rotating mixer for 5 mm, centri-
fuged, then returned to the rat over the next 20 mm.
Because some urine remained absorbed to the char-
coal, additional urine, again obtained from "donor
rats," was added prior to mixing. Preliminary in vi-
tro studies showed that this ratio of charcoal to
urine removed approximately 95% of the creatinine
and 99% of the uric acid.
The third technique consisted of essentially the
same methodology as the second technique except
that the charcoal was replaced by zirconium oxide.
The zirconium oxide (CCI Life Systems, Chats-
worth, California) was used in either the acetate or
chloride form. It has the property of exchanging the
acetate or chloride for other anions, polyvalent an-
ions being more strongly bound than monovalent
ones [10]. Preliminary in vitro studies using the ace-
tate form in a ratio of 100mg in I ml of urine showed
that it did not change the concentration of sodium,
potassium, chloride, urea nitrogen, uric acid, or
creatinine, but removed about 98% of the inorganic
phosphorus.
Series 3: Effect of infusing electrolyte solution
containing inorganic phosphorus on calcemic re-
sponse to PTE. In this series of experiments, rats
were prepared and operated on as for the other two
series, then all rats were injected with PTE and in-
fused with the appropriate volume of electrolyte so-
lution in a similar manner to the nonuremic con-
trols, as described above in series 1. This elec-
trolyte solution, however, contained, in addition,
varying amounts of inorganic phosphorus, added as
a neutral mixture containing dibasic sodium phos-
phate, 11.5 g, and monobasic potassium phosphate,
2.5 gIlOO dl. To determine the amount of phosphorus
to be given in the series-3 experiments, we calcu-
lated the total amount of inorganic phosphorus
which was returned to a rat when urine was rein-
fused and PTE (80 U/100 g) given, by measuring
the inorganic phosphorus concentration in a small
aliquot of urine (20 d) taken from each batch im-
mediately prior to reinfusion. The total quantity of
inorganic phosphorus infused with the urine was
found to be 39.6 2.9 mg (N = 3). The study was
then performed giving this total amount of inorganic
phosphorus in increasing increments during the ten
30-mm infusion periods, and three further studies
were carried out in which the total amount of phos-
phorus infused was 27.6 mg, 15.6 mg, and 7.8 mg,
respectively.
Bioche,nica/ methods. These were similar to
those described previously [9] except that inorganic
phosphorus was measured manually with a micro
modification of the method of Fiske and Subbarow
[11]; blood gases were measured using a Radio-
meter ABLI Acid Base Laboratory automated
blood gas analyzer (Radiometer Instruments, Co-
penhagen); sodium, potassium, and chloride were
measured using standard flame photometry; and
urea nitrogen was measured by a micro-
spectrophotometric method using 20% sulphuric
acid, diacetyl monoxime, and thiosemicarbazide.
All results are expressed as mean SENt, statisti-
cal analyses were performed using a Student's t test
for unpaired samples, and P values of <0.05 were
considered significant.
Results
The urine-reinfused rats in series 1 received in 5
hours a volume of urine passed during a period of
6.5 hours (mean, 14.9 1.3 ml; N = 39). The mean
serum creatinine in these animals, of 0.86 = 0.03
mgldl, was noted to be less than the mean serum
creatinine of 1.10 = 0.02 mgldl observed in rats in a
previous study [8] following 5 hours of ureter liga-
tion. This difference may be explained at least in
part by volume expansion.
Series 1. The results of series- 1 studies shown in
Table 1 demonstrate the difference in plasma cal-
cium, inorganic phosphorus, creatinine, and urea
nitrogen between groups of electrolyte and urine-
infused rats. Three pairs of studies are compared,
those given Lilly diluent, 40 UIlOO g PTE, and 80 U/
100 g PTE. In all instances, the creatinine and urea
nitrogen concentrations were significantly higher in
the urine-infused than in the electrolyte-infused
rats. In the diluent-treated groups, there was no sig-
nificant difference between plasma calcium and in-
organic phosphorus concentrations in urine-infused
rats and those concentrations in the electrolyte-in-
fused rats. In both of the PTE-treated groups, the
plasma calcium was significantly higher, and in-
organic phosphorus significantly lower, in the rats
which received electrolyte solution in comparison
with those given urine,P <0.001. The difference in
plasma calcium between urine- and electrolyte-in-
fused rats given PTE would have been slightly
greater had the small amount of calcium present in
the urine been added to electrolyte solution. As the
differences were highly significant without taking
this factor into account, no adjustment was made.
The plasma concentrations of sodium and potas-
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sium were similar in all of these groups (results not
shown).
To observe whether urine infusion alone has an
effect on the plasma calcium, we simply reinfused a
group of four rats with urine for 5 hours as de-
scribed above. The animals were not TPTX or given
PTE. The final plasma calcium concentration of
10.2 0.6 mg/dl was not significantly different from
that found in normal rats on a low-calcium diet (10.5
0.4 mg!dl, N = 10).
Series 2. The results of the series of studies de-
signed to investigate the nature of the impaired cal-
cemic response in urine-infused animals, that is, the
parathyroid resistance, are shown in Table 2. PTE,
80 U/l00 g, was used in all these studies because it
was noted (Table 1) that the difference in plasma
calcium between urine and electrolyte groups was
greater with the higher dose of PTE. The first row in
Table 2 shows the results when nontreated urine is
infused. This is the same study as that shown in the
last line of Table 1 and is included simply to facili-
tate comparisons. Ultrafiltration of the urine
through Amicon membranes of three different pore
sizes resulted in final plasma calcium values in these
groups of animals which were not statistically dif-
ferent from the nontreated-urine group. The theo-
retical molecular-weight retentivities of the three
membranes used, UM-20, UM-2, and UM-05, were
20,000, 1,000, and 500 daltons, respectively. As ex-
pected, none of the membrane treatments reduced
the urea nitrogen levels, although there was a slight
fall in creatinine in the UM-05 group.
When the urine was pretreated with activated
charcoal prior to reinfusion, the plasma creatinine
concentration fell to 0.37 0.01 mg/dl, a value simi-
lar to that in electrolyte-infused rats given the same
dose of PTE, 0.40 0.7 mg/dl. The urea nitrogen
level of 14.5 0.9 mg/dl was significantly lower
than the level in the nontreated urine group, 21.2
2.4 mg/dl, but still higher than in the electrolyte-in-
fused group. In spite of the effect of charcoal on
creatinine and, presumably, on many other sub-
Tablet. Biochemical results in TPTX rats reinfused with either urine or equivalent volumes of electrolyte solution, commencing
immediately after the injection of PTE or diluent and lasting for 5 hoursa
Treatment
group
No. of
rats
Plasma Ca
mg/dl
Plasma P,
mg/dl
Plasma creatinine
mg/dl
Plasma urea nitrogen
mg/dl
With diluent
Electrolyte infusion 10 6.5 0.1 12.2 0.4 0.38 0.01 6.4 0.3
Urine infusion II 7.4 0.4 13.3 0.7 0.81 0.03 28.6 2.5
P NS NS <0.001 <0.001
With 40 U/l00 g PTE
Electrolyte infusion 10 12.6 0.4 9.4 0.4 0.46 0.01 9.6 1.1
Urine infusion 18 10.6 0.2 13.2 0.5 0.87 0.04 28.0 1.9
P <0.001 <0.001 <0.001 <0.001
With 80 U/lOOg PTE
Electrolyte infusion 11 14.9 0.3 7.5 0.3 0.40 0.07 8.2 1.0
Urine infusion 10 12.0 0.3 11.7 0.4 0.90 0.04 21.2 2.4
P <0.001 <0.001 <0.001 <0.001
aValues are means SEM.
Table 2. Biochemical results in TPTX rats given PTE (80 U/lOO g) and reinfused with urine which was treated by several different
techniques prior to reinfusiona
Methods of urine treatment No. Ca Pt Creat. BUN
None 10 12.0 0.3 11.7 0.4 0.9 0.04 21.2 2.4
Amicon membrane UM20' 7 11.5 0.4 12.7 0.8 0.86 0.03 26.5 2.6
Amicon membrane UM025 5 11.9 0.4 15.4 0.6 0.88 0.04 26.0 3.6
Amicon membrane UMO5" 7 12.5 0.3 12.2 1.9 0.68 o•06d 21.1 3.5
Activated charcoal 8 12.3 0.3 11.3 0.7 0.37 0.0lc 14.5 0.9e
Zirconium oxide 10 15.1 0.4 7.1 0.3c 0.81 0.05 18.5 1.2
a Values are means 5EM.
Molecular weight cut-off for UM-20 was 20,000; for UM-02, 1000; and for UM-05, 500 daltons.
ep < 0.001, significantly different from nontreated group.
d P < 0.02, significantly different from nontreated group.
P < 0.05, significantly different from nontreated group.
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stances known to accumulate in uremia, the final
plasma calcium and phosphorus concentrations in
the group were not significantly different from the
nontreated-urine group.
When the urine was treated, however, with zirco-
nium oxide (acetate form) prior to reinfusion, the
final plasma calcium and inorganic phosphorus con-
centrations were 15.1 0.4 mg/dl and 7.1 0.3 mg/
dl, respectively. Both these values were statistically
different, higher in the case of calcium and lower in
the case of inorganic phosphorus, from those values
in the nontreated urine group, 12.0 0.3 mg/dl and
11.7 0.4 mg/dl, respectively (P < 0.001). They
were not statistically different from the calcium and
inorganic phosphorus values obtained in elec-
trolyte-infused rats given 80 U/lOO g PTE, 14.9
0.3 and 7.5 0.3 mgldl, respectively (row 5, Table
1). The plasma creatinine and urea nitrogen concen-
trations were similar in the zirconium-oxide-treated-
urine group and the nontreated-urine group. These
results, therefore, strongly suggest that retention of
inorganic phosphorus is the major cause of the im-
paired calcemic response to PTE in the urine-rein-
fused rats.
Further studies were carried out to determine the
effect on the acid-base status of groups of rats that
had been reinfused with urine treated with either
the chloride or the acetate form of zirconium oxide.
Five groups of rats were used: those reinfused with
urine; those reinfused with electrolyte solution;
those reinfused with zirconium-oxide (acetate form)
-treated urine; those reinfused with zirconium-oxide
(chloride form)-treated urine; and a group reinfused
with zirconium-oxide (chloride form) -treated urine
which had inorganic phosphorus added back to the
urine after treatment. The total amount of phos-
phorus added back to the urine was 38 mg, approxi-
mately the same amount that rats would receive if
they were simply reinfused with urine (see Meth-
ods, series 3). At the finish of the experiment, about
3 ml of blood was collected anaerobically in a hepa-
rinized syringe for measurement of blood gases,
plasma calcium, inorganic phosphorus, BUN, and
creatinine.
The results shown in Table 3 again demonstrate
that urine treated with zirconium oxide, chloride or
acetate form, does not impair the calcemic response
to PTE in contrast to nontreated urine. This table
also shows that nontreated urine reinfusion pro-
duces a modest fall in plasma bicarbonate, 19.4
0.8 mEq/liter compared with 23.8 0.6 mEq/liter in
electrolyte-infused rats. Zirconium oxide treatment
in the chloride form did not correct the acidosis, but
the acetate-form-treated group had a plasma bi-
carbonate concentration of 25.8 0.4 mEq/liter,
slightly but significantly higher than that of the elec-
trolyte-infused rats (P < 0.02). The effect of the zir-
conium oxide (acetate form) in correcting the bicar-
bonate concentration is probably due to the ex-
change of inorganic phosphorus for acetate which is
then metabolized to bicarbonate in vivo [12]. The
results on the last line of Table 3 show that adding
inorganic phosphorus back to the zirconium-oxide
(chloride form) -treated urine results in an even
more marked depression of the calcemic response
to PTE than seen in the urine-infused group (9.8
0.3 mg/dl compared with 12.3 0.3 mg/dl, P <
0.001). This occurred in spite of the fact that there
was no significant difference between the plasma in
organic phosphorus concentrations of the two
groups, 10.9 0.3 mg/dl in the zirconium oxide-
treated phosphate-added urine group compared
with 11.4 0.4 in the nontreated urine group.
Because of the theoretical possibility that zirconi-
um oxide has a calcemic action, two groups of
TPTX rats were studied using the basic protocol de-
scribed above; PTE was not given. One group was
reinfused with the electrolyte solution, and the oth-
er group was reinfused with electrolyte solution that
had previously been treated with the acetate form of
Table 3. Acid-base status and calcemic response to PTE (80 U/100 g) in TPTX rats reinfused with electrolyte solution, urine,
zirconium-oxide ([ZrO] acetate or chloride form) -treated urine and urine treated with ZrO (chloride form) to which inorganic phosphorus
(38 mg) was added back to the urine prior to reinfusiona
Group
No.
of rats
Plasma Ca
mgldl
Plasma P1
mgldl
Plasma creat.
mg/dl pH
Pco2
mm Hg
11C03
mEq/liter
Electrolyte infused 9 l5.8 0.7 72h 0.3 0.42 0.02 754e 0.09 29.7 1.1 23.8" 0.6
Urine infused 10 12.3 0.3 11.4 0.4 0.70 0.03 7.40 0.02 31.4 1.6 19.4 0.8
ZrO (acetate) -treated urine infused 9 15.5" 0.5 73b 0.3 0.74 0.03 7.49 0.02 34.6 1.6 25.8" 0.4
ZrO (Cl) -treated urine
ZrO (CI) -treated urine P, added infu
12
sed 8
16.6" 0.6
9.8" 0.3
6.7' 0.3
10.9 0.3
0.74 0.01
0.72 0.02
7.34 0.02
7.51" 0.01
37.2
29.5
1.7
1.8
19.3 0.4
23.lc 0.7
Values are means SaM.
"P < 0.001, significantly different from urine-infused group.
P < 0.01, significantly different from urine-infused group.
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zirconium oxide. The final plasma calcium concen-
trations were similar: 6.4 0.4 mg/dl in the elec-
trolyte group and 7.0 0.4 mg/dl in the "zirconium
group." These results suggest that zirconium itself
does not have any influence on the plasma calcium
concentration following TPTX.
Series 3. To examine the effect of inorganic phos-
phorus retention alone, rather than the effect of all
substances present in rat urine, on the impaired cal-
cemic response to PTE, we carried out a series of
experiments where increasing amounts of inorganic
phosphorus were added to the electrolyte solution.
The maximum dose of inorganic phosphorus used
was the same total amount that we had measured in
the urine that was reinfused. Four different doses of
inorganic phosphorus were used, as described in
the methods section, to determine the relationship
between the amount of inorganic phosphorus given
and the final plasma calcium concentration. In each,
PTE was given in a dose of 80 U/100 g. The results
of these studies are shown in Table 4. The first row
in this table shows the results of the same study that
appears in rowS, Table I; this is included as a "zero
phosphate" control. It can be seen from this table
that as increasing amounts of inorganic phosphorus
are infused, the final plasma calcium concentration
falls and the plasma phosphorus rises. No such
trend was noted with the plasma creatinine or so-
dium concentration, but there was a fall in plasma
potassium with increasing doses of inorganic phos-
phorus. The final plasma calcium concentration was
plotted against the amount of phosphorus infused,
and a highly significant negative correlation was
found, r = 0.915, P < 0.001 (Fig. 1). A significant
negative correlation was also noted when the final
plasma inorganic phosphorus concentration was
plotted against the final plasma calcium concentra-
tion (Fig. 2). These studies indicate that the total
amount of phosphorus present in the urine that was
given back to the animal, is clearly sufficient to
depress the calcemic response to PTE to at least the
level which was observed (12.0 0.3 rngldl, see
Table 1, last row). We also noted that there was on-
ly a slight rise in plasma inorganic phosphorus be-
tween the zero-inorganic-phosphorus-dose group
and the 15.6-mg-dose group; that is, plasma in-
organic phosphorus levels were 7.5 0.3 mgldl and
8.4 0.4 mg/dl, respectively. This slight rise in
plasma inorganic phosphorus, however, was re-
sponsible for a much greater fall in plasma calcium,
which dropped from 14.9 0.3 to 12.3 0.2 mg/dl.
It is thus possible, that in these conditions, the
plasma inorganic phosphate concentration does not
necessarily reflect accurately the phosphorus con-
tent in other body compartments such as bone,
which may be important in the calcemic response to
PTE.
Discussion
We have demonstrated that uremia causes resis-
tance to the calcemic action of PIE in an animal
model where the kidneys can reasonably be as-
sumed to be filtering normally, showing that the fac-
tors responsible are present in the urine. Although
the same conclusion could be made tentatively in a
uremic model produced by ureter ligation, it has
been shown in anatomical studies of kidneys that
abnormalities of tubular cells occur after 24 hours of
ureter ligation [13]. Our model has avoided the
problem of damage to tubular cells by hydrostatic
pressure, and therefore if any disorder of kidney
cell function is present it must be assumed to be
due to an effect of the urine reinfusion.
It has been suggested both by us [8] and by anoth-
er group [7] that uremic factors may play a part in
the genesis of PTH resistance. This latter group had
previously shown in a 24-hour dog renal-failure
model, that vitamin D metabolites may also be im-
portant in PTH resistance. In our study, we demon-
strated that a deficiency of vitamin D metabolites
was not the cause of the PTH resistance after 5
hours of ureter ligation in the rat.
In this paper we have also presented evidence
that parathyroid resistance is not due to traditional
Table 4. Biochemical results in TPTX rats, 5 hours after PTH (80 U/l00 g), who were infused with electrolyte solution, equal in volume to
the amount of urine excreted, containing increasing quantities of P1 from 0 to 39.6 mga
Total dose infused P1
mg
No. of
rats
Plasma Ca
mgldl
Plasma P1
mgldl
Plasma creat.
mgldl
Plasma Na
mEq/liter
Plasma K
mEqiliter
Zero 10 14.9 0.3 7.5 0.3 0.40 0.02 142 1 6.0 0.2
7.8 9 13.9 0.3 8.2 0.3 0.36 0.02 139 1 6.0 0.3
15.6 8 12.3 0.2 8.4 0.4 0.35 0.02 139 1 5.7 0.3
27.6 8 11.2 0.3 10.0 0.2 0.35 0.02 142 1 5.1 0.2
39.6 8 9.3 0.3 13.4 0.5 0.36 0.01 143 1 5.0 0.1
a Values are means SEM.
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uremic toxins. Most small molecular-weight sub-
stances known to accumulate in uremia, such as in-
doles, phenols, organic acids, amines, and guani-
dine compounds [14], would have been removed by
the activated charcoal [15]. The fact that the char-
coal-treated group did not develop an elevation of
plasma creatinine indicates that an adequate char-
coal-to-urine ratio was used. Small molecular-
weight substances that are not well removed by the
charcoal are inorganic ions and urea [15]. Middle
molecules were also excluded as the cause of PTE
resistance by the Amicon membrane experiments,
as parathyroid resistance was still present when
urine, which had been passed through a membrane
of a molecular-weight cut-off of 500 daltons, was in-
fused.
The final plasma calcium concentration of the
group reinfused with zirconium-oxide (acetate
form) -treated urine, 15.1 0.4 mgldl (Table 2), was
similar to the final plasma calcium concentration
noted in the group reinfused with electrolyte solu-
tion, 14.9 0.3 mg!dl. Both groups were given
PTE, 80 U/lOO g; thus, it is likely that the zirconium
oxide treatment removed the factor or factors re-
sponsible for the PTE resistance from the urine.
The other possibility is that zirconium-oxide-treated
urine has, itself, a calcemic action. This would be a
highly unlikely explanation, because it is known to
be an extremely insoluble substance in the pH range
of urine [16]. In any event, this possibility was ex-
cluded by showing no difference in the final plasma
calcium concentration of TPTX rats infused with ei-
ther electrolyte solution or electrolyte solution pre-
treated with zirconium oxide. Therefore, the only
way in which it could have altered the urine would
be by the addition of acetate in exchange for what-
ever substances it removed. Because the zirconium-
oxide-treated urine maintained the plasma phos-
phorus at a concentration of 7.1 0.3 mgldl, com-
parable to the level of 7.5 0.3 mg!dl noted in the
electrolyte-infused group given the same dose of
PTE, we believe that it is the inorganic phosphorus
in the reinfused urine which is responsible for the
PTE resistance. Other substances which theoreti-
cally could have been removed from the urine by
the zirconium oxide treatment are fluoride, bicar-
bonate, sulphate, and some organic anions. It is un-
likely that fluoride would be found in the urine, and
as the urine had a pH less than 7.0, very little bi-
carbonate would be present [17]. The organic acids
can reasonably be assumed to be unimportant; oth-
erwise their removal by the activated charcoal
would have affected the calcemic response. The zir-
conium oxide treatment used in this experiment
causes acetate to be added to the urine and, as
stated above, this would be metabolized in vivo to
bicarbonate and would tend to reverse the mild
acidosis caused by the urine infusion.
It is conceivable that resistance to the calcemic
action of PTE could be related to the development
of renal-failure-induced acidosis. The results shown
on Table 3 indicate that this is not likely to be the
case. When urine treated with the acetate form of
zirconium oxide is reinfused, the uremic acidosis
was reversed, but when the chloride form of zirco-
nium-oxide-treated urine is reinfused, there was no
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Fig. 1. Relationship between the amount of inorganic phosphorus(P) added to the infused electrolyte solution and the final plasma
calcium. Plasma calcium was measured 5 hours after injection of
PTE, 80 U/100 g, and initiation of electrolyte infusion.
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Fig. 2. Plot of the final plasma phosphorus concentration against
the final plasma calcium concentrations from the same studies
shown in Table 4 and Fig. I.
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reversal of the uremic acidosis. In both instances
the calcemic response to PTE was not significantly
different from the electrolyte-infused group and sig-
nificantly higher than the nontreated-urine group,
suggesting that acidosis is not an important factor in
the development of parathyroid resistance in this
model.
To confirm our impression that phosphorus reten-
tion is the cause of the parathyroid resistance, we
carried out the experiments shown in Table 4. It is
quite clear from these studies that the final plasma
calcium concentration in this experimental model is
inversely proportional to the amount of inorganic
phosphorus present in reinfused electrolyte solution
(Fig. 1) (therefore to the amount present in the
urine) and to final inorganic phosphorus concentra-
tion (Fig. 2). It was noted from these studies that
the total amount of inorganic phosphorus contained
in the reinfused urine (about 40 mg) did not produce
as much depression of the plasma calcium concen-
tration as when a similar amount of phosphorus was
added to the electrolyte solution. The final calcium
was 12.0 0.3 mg/dl in the urine-reinfused group
and 9.3 0.3 mgldl in the group which received
39.6 mg of inorganic phosphorus in the electolyte
solution. Although the reason for this difference
could have been due to the calcium present in the
reinfused urine, but not present in the electolyte so-
lution, addition of an appropriate amount of calcium
to the phosphate-containing electrolyte solution re-
sulted in a final plasma calcium concentration of
8.6 0.5. This is still significantly less than that in
the urine-infused group. It therefore seems that
some still unidentified factors must be responsible
for the difference.
Further evidence for inorganic phosphorus being
the cause of parathyroid resistance is shown on the
last line of Table 3. In this study, inorganic phos-
phorus was added back to the urine after its remov-
al by the chloride form of zirconium oxide. The final
plasma calcium concentration in this study was
again noted to be lower than when urine alone (con-
taining a similar amount of inorganic phosphorus)
was infused, in spite of the fact that the plasma in-
organic phosphorus concentrations were similar,
11.4 0.4 mg/dl in the nontreated-urine group and
10.9 0.3 mg!dl in the zirconium-treated, phos-
phate-added group. This experiment clearly shows
that the amount of inorganic phosphorus present in
the urine is enough to be responsible for the im-
paired calcemic response to PTE noted when urine
is reinfused.
The results presented in this paper indicate that
inorganic phosphorus retention is entirely respon-
sible for the parathyroid resistance phenomenon in
our animal model. This conclusion is not supported
by the work of Massry et al, who were able to dem-
onstrate an impaired calcemic response to PIE in-
fusion in patients with acute renal failure during ei-
ther the oliguric phase of acute renal failure when
the serum inorganic phosphorus concentration was
elevated or the diuretic phase when the serum in-
organic phosphorus concentration was normal [2].
Major differences exist between this study and our
animal experiment; the patients were initially stud-
ied many days after the onset of acute renal failure,
ample time for abnormalities in vitamin D metabo-
lism to have developed, and as mentioned earlier in
this discussion this has been shown to be an impor-
tant factor in the cause of parathyroid resistance in
uremia of greater than 24 hours' duration [4]. In ad-
dition, there is suggestive evidence from our pres-
ent studies shown in Table 4, lines 2 and 3, that
changes in total phosphorus content of an animal
may not necessarily be directly related to the
plasma inorganic phosphorus concentration. It is
certainly conceivable that the hyperphosphatemia
that occurs during the oliguric phase of acute renal
failure may not reflect the body inorganic phos-
phorus stores.
Although the animal model used in this study was
one of mild uremia of very short duration, it has
been shown previously that parathyroid resistance
is present in mild uremia [3]. If factors other than
phosphate retention were important in early para-
thyroid resistance in our model, a degree of im-
paired calcemic response would have been ex-
pected to remain in spite of prevention of the phos-
phate retention, and as can be seen from Table 3,
this is clearly not the case.
The mechanism by which inorganic phosphorus
retention impairs the calcemic response to the PIE
has not been demonstrated in this study. In humans
with hypercalcemia of various etiologies, it has
been clearly shown that either oral or intravenous
phosphate infusions will lower the serum calcium
concentration, but again the mechanism was not
certain [18]. In another clinical study, the hypocal-
cemic effect of phosphate infusion was investigated,
and it was concluded that this effect was unrelated
to any particular endocrine activity but probably
due to physicochemical precipitation of calcium
phosphate, as its solubility product is exceeded
[19]. This latter study did not show whether this
precipitation was in bone or soft tissue, nor did it
exclude the possibility that a rising calcium and in-
organic phosphorus product may inhibit calcium
transport from bone into the extracellular fluid.
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It is quite possible that inorganic phosphorus
does not directly give rise to parathyroid resistance,
and the phenomenon may be simply a physico-
chemical precipitation of calcium and inorganic
phosphate when the levels of these two ions rise
above their solubility product. That is to say, this
mechanism is quite independent of the calcemic ac-
tion of PTH. The other possibility is that the in-
crease in extracellular inorganic phosphorus due to
uremia somehow impairs the PTH-mediated in-
crease in calcium transport from bone to extra-
cellular fluid.
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